Business
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
- Dr. Brake formerly held leadership roles at Takeda Oncology, including Vice President, Global Project Leader in the Oncology Therapeutic Area and Head, U.S.
About this update from Corbus Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"- Dr. Brake formerly held leadership roles at Takeda Oncology, including Vice President, Global Project Leader in the Oncology Therapeutic Area and Head, U.S. Medical Affairs, Oncology Business Unit\n - Appointment solidifies Company's commitment to its anti-αvβ8 integrin program and evolving its R&D platform further into immuno-oncology\n\n\nNORWOOD, Mass., Dec. 7, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\"Corbus\" or the \"Company\") today announced the appointment of Rachael Brake, Ph.D., as Chief Scientific Officer, furthering the Company's mission of connecting innovation to purpose. Dr. Brake will build upon Corbus' commitment to immuno-oncology and joins the Company following the recent acquisition of monoclonal antibodies that inhibit TGFβ activation. \n\n \n \n \n \n \n \n\n \nDr. Brake most recently served at Takeda Pharmaceuticals where she held multiple leadership roles across the R&D continuum, including serving as Vice President, Global Project Leader in Oncology. In this position, she managed a portfolio of programs and cross-functional teams responsible for the preclinical and clinical exploration of various solid tumor drug candidates spanning diverse mechanisms of action. She is experienced in early- and late-stage clinical development, regulatory approvals (ALUNBRIG®, EXKIVITY™), program externalizations (DAY101, sapanisertib), and commercialization efforts. In her most recent role as the Head, U.S. Medical Affairs, in the Oncology Business Unit, Dr. Brake developed a medical strategy for Takeda Oncology's portfolio and emerging immune-focused pipeline. Prior to her tenure at Takeda, Dr. Brake held leadership roles in Research at Amgen Inc. and Millennium Pharmaceuticals, Inc.\nDr. Brake will be responsible for advancing Corbus' pipeline of TGFβ-targeting therapeutics as well as current endocannabinoid system targeting drug candidates. She will also play a key role in shaping the Company's broader scientific strategy to help guide future business development opportunities and refinement of the research scope for the Company. \nYuval Cohen, Ph.D., Chief Executive Officer of Corbus said, \"Rachael brings a depth of industry experience coupled with a genuine passion for oncology drug development. Her expertise, leadership and vision will be critical to advancing our existing pip...